Testosterone Cypionate Geriatric (65+) Monitoring

Why Geriatric Monitoring Differs From Standard Adult Protocols

Older men are not simply older versions of a 40-year-old hypogonadal patient. The physiologic changes that accumulate after age 65 alter every pharmacokinetic and pharmacodynamic parameter that matters for testosterone therapy.

Age-Related Physiology That Changes the Risk Profile

Renal mass declines roughly 1% per year after age 50, reducing glomerular filtration rate and slowing elimination of testosterone metabolites [1]. Erythropoietic sensitivity to androgens increases with age, meaning the same serum testosterone level that produces a hematocrit of 47% in a 45-year-old may produce 52% or higher in a 72-year-old [2]. Hepatic first-pass capacity drops, although this matters less for the injectable cypionate ester than for oral androgens.

Body composition shifts compound these changes. Older men carry more adipose tissue, which aromatizes testosterone to estradiol at a higher rate. Higher estradiol in men is associated with gynecomastia and fluid retention, both of which require monitoring that is often skipped in younger cohorts [3].

What the T-Trials Established

The Testosterone Trials (T-Trials) are the most rigorous evidence base for testosterone therapy in men 65 and older. Published in the New England Journal of Medicine in 2016, the T-Trials enrolled 790 men aged 65 or older with a serum testosterone below 275 ng/dL and at least one of three symptoms: reduced sexual function, reduced vitality, or reduced physical function [4].

After 12 months of testosterone gel (titrated to a serum level of 500 ng/dL), the trials showed statistically significant improvements in sexual function (International Index of Erectile Function score increase of 2.64 points, P<0.001) and modest but significant improvements in walking distance (average 20.5 additional meters on a 6-minute walk test, P=0.02) [4]. Vitality scores improved, but the difference did not meet the pre-specified threshold for clinical significance.

The cardiovascular sub-trial (the TRAVERSE predecessors) found that noncalcified coronary artery plaque volume increased by a mean of 41 mm³ more in the testosterone arm than in the placebo arm (P=0.002), a finding that placed cardiovascular monitoring at the center of geriatric TRT protocols [5].

"The clinical implication is that testosterone therapy in older men should be individualized, with careful attention to cardiovascular risk factors," wrote the T-Trials investigators in a secondary analysis published in JAMA Internal Medicine [5].

Baseline Workup Before Starting Testosterone Cypionate in Men 65+

Every geriatric patient deserves a thorough baseline evaluation before the first injection. Skipping this step eliminates the reference values needed to detect harm.

Laboratory Panel

Order all of the following at baseline [6]:

• Total testosterone (morning, fasting, two separate measurements on different days to confirm hypogonadism)
• Free testosterone (especially relevant in men with obesity or altered sex hormone-binding globulin)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify primary vs. Secondary hypogonadism
• Complete blood count with hematocrit and hemoglobin
• Comprehensive metabolic panel including eGFR and liver function tests
• PSA
• Lipid panel
• HbA1c or fasting glucose
• Estradiol (sensitive assay)
• SHBG

A serum testosterone below 300 ng/dL on two morning measurements, combined with confirmed symptoms, meets the American Urological Association and Endocrine Society criteria for initiating treatment in men 65 and older [6].

Cardiovascular and Functional Baseline

Beyond labs, the baseline visit should include [7]:

• Blood pressure measurement
• Body weight and BMI
• Falls risk screen using the CDC STEADI three-question tool
• Medication reconciliation for drugs that raise hematocrit (e.g., erythropoiesis-stimulating agents) or increase cardiovascular risk
• DXA scan if the patient has not had one in the past two years, particularly in men with a history of fragility fracture or long-term glucocorticoid use

Men with a 10-year ASCVD risk above 20% calculated via the ACC/AHA Pooled Cohort Equations should have an explicit cardiovascular risk-benefit discussion documented before the first dose [7].

Monitoring Schedule: The First 12 Months

The first year of testosterone cypionate therapy in an older man is the period of highest surveillance density. Most adverse events, particularly hematocrit elevation and early cardiovascular signals, emerge in this window [8].

Months 1 Through 3

Draw serum testosterone 7 days after the weekly injection (trough for once-weekly dosing) or at the midpoint between injections for twice-weekly protocols. The Endocrine Society guideline targets a mid-cycle serum testosterone of 400 to 700 ng/dL for older adults, which is deliberately lower than the 500 to 900 ng/dL range sometimes used in younger men [6].

Repeat hematocrit at 6 weeks. If hematocrit rises above 54%, withhold therapy, evaluate for secondary polycythemia (sleep apnea, chronic hypoxia), and do not reinitiate until hematocrit falls below 50% [6]. In a 2013 meta-analysis of 51 randomized controlled trials (N=4,808), testosterone therapy increased hematocrit by an average of 3.2 percentage points vs. Placebo, with older men showing the largest absolute increases [2].

Check PSA at 3 months. A rise of more than 1.4 ng/mL above baseline within the first 3 months warrants urology referral regardless of absolute value [6].

Months 3 Through 12

After the 3-month check, the next full lab panel occurs at 6 months and again at 12 months. Each panel includes total testosterone, hematocrit, PSA, and a lipid panel. Estradiol is rechecked if the patient reports breast tenderness or fluid retention.

Blood pressure is measured at every clinic visit. Testosterone cypionate can cause sodium and water retention, raising systolic blood pressure by 3 to 5 mmHg in susceptible individuals [9]. In men already managing hypertension with two or more agents, this rise may require antihypertensive dose adjustment.

Falls risk is reassessed at each visit. While improved muscle mass and walking distance were documented in the T-Trials physical function sub-trial, the same cohort had a higher rate of edema-related mobility complaints in the testosterone arm [4]. Ankle edema reduces proprioception and increases fall probability in older adults.

Long-Term Monitoring: Year 2 and Beyond

After the first 12 months, monitoring frequency reduces, but never drops below an annual cadence for any parameter.

Annual Laboratory Requirements

The Endocrine Society recommends annual measurement of [6]:

• Total testosterone (mid-cycle)
• Hematocrit
• PSA
• Lipid panel
• eGFR and liver function

Bone mineral density via DXA is repeated every 1 to 2 years in men who had osteopenia at baseline. One randomized trial (N=211, mean age 74) showed that 12 months of testosterone therapy increased vertebral bone density by 7.5% vs. Placebo in hypogonadal older men, but this benefit was concentrated in those with baseline total testosterone below 200 ng/dL [10].

Cardiovascular Monitoring After Year 1

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 (mean age 63) with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk [11]. At a median follow-up of 33 months, testosterone therapy was non-inferior to placebo for the primary composite endpoint of MACE (major adverse cardiovascular events): 7.0% in the testosterone arm vs. 7.3% in placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) [11].

"These findings provide reassurance for men who require testosterone therapy but have concerns about cardiovascular safety," stated the TRAVERSE authors, though they noted the trial was not powered to detect differences in specific subgroups such as men over 75 [11].

For men 75 and older, the cardiovascular evidence remains thinner. Annual cardiovascular review including blood pressure, weight, lipid panel, and symptom screen for angina or dyspnea should be documented explicitly in the chart.

Prostate Monitoring in Men 65+

Prostate cancer risk increases with age independent of testosterone. Men 65 and older starting testosterone cypionate should have a baseline PSA and digital rectal exam. After that, PSA monitoring follows the American Cancer Society guideline for age-appropriate screening, layered on top of the testosterone-specific monitoring schedule [12].

If PSA velocity exceeds 0.4 ng/mL per year over any 2-year period while on therapy, urology referral is indicated. Testosterone therapy does not appear to cause de novo prostate cancer, but it may accelerate growth of subclinical disease, which is more prevalent in older men [6].

Hematocrit Management in Older Men

Hematocrit elevation is the most common laboratory abnormality requiring dose adjustment in older men on testosterone cypionate. The mechanism is direct stimulation of erythropoietin production and suppression of hepcidin, both of which amplify red cell mass [2].

Dose Adjustment Thresholds

| Hematocrit | Action | |---|---| | <54% | Continue current dose | | 54 to 56% | Reduce dose or extend injection interval to every 10 to 14 days | | >56% | Withhold therapy; evaluate for secondary polycythemia | | Falls below 50% after hold | May reinitiate at lower dose with 6-week recheck |

Therapeutic phlebotomy is an option for patients in whom dose reduction causes return of debilitating hypogonadal symptoms, but this should be used sparingly and only after excluding secondary causes of erythrocytosis (sleep apnea, smoking, chronic lung disease) [8].

Sleep Apnea Screening

Testosterone worsens obstructive sleep apnea in susceptible individuals by increasing upper airway collapsibility and altering central respiratory drive [13]. In men 65 and older, the prevalence of undiagnosed OSA exceeds 40% in some populations [13]. Screen with the STOP-BANG questionnaire at baseline and repeat if hematocrit rises unexpectedly or the patient reports new daytime somnolence.

Drug-Drug Interactions in the Geriatric Polypharmacy Context

Men 65 and older take an average of 5.8 prescription medications per day [14]. Testosterone cypionate interacts with several drug classes common in this age group.

Warfarin

Testosterone inhibits CYP2C9, the primary enzyme responsible for S-warfarin metabolism. Concurrent use raises INR by approximately 25 to 30% in anticoagulated patients [15]. Check INR within 2 to 4 weeks of any testosterone dose change in men on warfarin.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity, which can reduce fasting glucose by 15 to 25 mg/dL in hypogonadal men with type 2 diabetes [16]. This improvement is beneficial but can cause hypoglycemia if sulfonylurea or insulin doses are not adjusted. Review diabetic medications at the 3-month and 6-month visits.

Corticosteroids

Chronic glucocorticoid use suppresses the hypothalamic-pituitary-gonadal axis and contributes to secondary hypogonadism. If the patient is on prednisone 5 mg/day or more for more than 3 months, hypogonadism may partly resolve if steroids are tapered. Reassess testosterone levels before attributing hypogonadism entirely to primary gonadal failure.

Deprescribing: When to Stop Testosterone Cypionate in Older Men

Deprescribing testosterone cypionate is clinically appropriate in several scenarios, and the decision framework below supports a structured approach.

Indications to Discontinue

Discontinue testosterone cypionate when any of the following apply [6]:

1. No symptomatic benefit after 6 months at a therapeutic serum testosterone level (400 to 700 ng/dL confirmed on mid-cycle draw).
2. Hematocrit persistently above 54% despite dose reduction to 50 mg weekly and exclusion of secondary causes.
3. New diagnosis of prostate cancer (any grade) or a PSA rise that prompts active surveillance entry.
4. New MACE event (myocardial infarction, stroke, unstable angina) within 6 months.
5. Patient preference after a fully informed benefit-risk discussion.

How to Taper

Testosterone cypionate does not require a formal pharmacologic taper because exogenous testosterone suppresses LH and FSH. Abrupt discontinuation will cause a period of hypogonadism lasting 3 to 6 months while the hypothalamic-pituitary-gonadal axis recovers, provided primary gonadal function was intact before treatment started [6]. Warn patients about this recovery window and schedule a testosterone level check 8 to 12 weeks after the last injection.

In men with confirmed primary hypogonadism (elevated LH and FSH at baseline), the HPG axis will not recover after stopping. These patients may require a more detailed discussion about the durability of their decision to discontinue.

Dosing Guidance Specific to Men 65+

Standard geriatric dosing of testosterone cypionate is 50 to 100 mg intramuscularly or subcutaneously once weekly. The once-weekly schedule reduces peak-to-trough swings compared with the traditional every-2-week protocol, which produced supraphysiologic peaks near 1,200 ng/dL followed by troughs below 200 ng/dL, both of which are outside the safe range for older men [17].

Subcutaneous injection (using a 25-gauge, 5/8-inch needle into abdominal fat) produces a slower absorption curve, reducing peak testosterone levels by approximately 15 to 20% compared with intramuscular injection at equal doses [17]. This flatter curve may be preferable in men who are most susceptible to hematocrit spikes.

Dose titration should be conservative. Increase by no more than 25 mg increments at each 6-week reassessment until the mid-cycle target of 400 to 700 ng/dL is achieved.